Google+ Facebook Twitter Twitter

Neutralising antibodies against SARS-CoV-2

A trio of papers describe newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV.

Several of these showed protective, neutralising capabilities, offering promising therapeutic leads, and eight antibodies from one analysis were discovered to cross-react with a related bat-specific coronavirus – with implications for the identification of broadly neutralising antibodies to protect against potential future coronavirus outbreaks.

Philip Brouwer and colleagues isolated 403 monoclonal antibodies from three convalescent COVID-19 patients, showing that the patients had strong immune responses against the viral spike.

Thomas Rogers and colleagues used a high-throughput pipeline to isolate and characterise monoclonal antibodies from convalescent donors, selecting for antibodies that bind to the viral spike. Anna Wec and colleagues isolated and characterised hundreds of antibodies against the viral spike of SARS-CoV-2 from the memory B cells of a SARS-CoV survivor.

Picture Credit | Science Photo Library

Related Articles

Biomedical scientists honoured

Two biomedical scientists who are IBMS members were acknowledged in the Queen’s Birthday Honours this year:

IBMS President presents to MPs

IBMS President Allan Wilson gave evidence at a COVID-19 hearing to a select committee of MPs and Members of the Lords in October.

"Trust and inequality fuelling COVID-19 spread"

Trust in public institutions is linked to fewer COVID-19 deaths – however, trust and belonging to groups is associated with more deaths.

Medical eponyms (part 2): Aloysius Alzheimer

This is the second of selected short biographies of persons whose names are directly used for diseases, conditions, syndromes or tests familiar to those working in clinical pathology laboratories.